Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Byers LA, et al. Among authors: papadimitrakopoulou v. Mol Cancer Ther. 2010 Jun;9(6):1755-63. doi: 10.1158/1535-7163.MCT-09-1047. Epub 2010 Jun 8. Mol Cancer Ther. 2010. PMID: 20530716 Free PMC article.
Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck.
Hutcheson KA, Lewin JS, Holsinger FC, Steinhaus G, Lisec A, Barringer DA, Lin HY, Villalobos S, Garden AS, Papadimitrakopoulou V, Kies MS. Hutcheson KA, et al. Among authors: papadimitrakopoulou v. Head Neck. 2014 Apr;36(4):474-80. doi: 10.1002/hed.23330. Epub 2013 Jun 18. Head Neck. 2014. PMID: 23780650 Free PMC article. Clinical Trial.
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR Jr, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Massarelli E, et al. Among authors: papadimitrakopoulou v. Ann Oncol. 2015 Jul;26(7):1476-80. doi: 10.1093/annonc/mdv194. Epub 2015 May 29. Ann Oncol. 2015. PMID: 26025965 Free PMC article. Clinical Trial.
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Haddad RI, et al. Among authors: papadimitrakopoulou v. Ann Oncol. 2019 Mar 1;30(3):471-477. doi: 10.1093/annonc/mdy549. Ann Oncol. 2019. PMID: 30596812 Free PMC article. Clinical Trial.
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Kim ES, et al. Among authors: papadimitrakopoulou v. Cancer. 2005 Aug 1;104(3):561-9. doi: 10.1002/cncr.21188. Cancer. 2005. PMID: 16028213 Free article. Clinical Trial.
DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia.
Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM, Mao L. Saintigny P, et al. Among authors: papadimitrakopoulou v. Clin Cancer Res. 2009 Oct 1;15(19):6284-91. doi: 10.1158/1078-0432.CCR-09-0498. Epub 2009 Sep 22. Clin Cancer Res. 2009. PMID: 19773378 Free PMC article. Clinical Trial.
209 results